Literature DB >> 29528173

A Readily Accessible Class of Chiral Cp Ligands and their Application in RuII -Catalyzed Enantioselective Syntheses of Dihydrobenzoindoles.

Shou-Guo Wang1, Sung Hwan Park1, Nicolai Cramer1.   

Abstract

Chiral cyclopentadienyl (Cpx ) ligands have a large application potential in enantioselective transition-metal catalysis. However, the development of concise and practical routes to such ligands remains in its infancy. We present a convenient and efficient two-step synthesis of a novel class of chiral Cpx ligands with tunable steric properties that can be readily used for complexation, giving Cpx RhI , Cpx IrI , and Cpx RuII complexes. The potential of this ligand class is demonstrated with the latter in the enantioselective cyclization of azabenzonorbornadienes with alkynes, affording dihydrobenzoindoles in up to 98:2 e.r., significantly outperforming existing binaphthyl-derived Cpx ligands.
© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  asymmetric catalysis; cyclization; cyclopentadienyl ligands; ligand design; ruthenium

Year:  2018        PMID: 29528173     DOI: 10.1002/anie.201802244

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN: 1433-7851            Impact factor:   15.336


  3 in total

1.  The (not so) simple prediction of enantioselectivity - a pipeline for high-fidelity computations.

Authors:  Rubén Laplaza; Jan-Grimo Sobez; Matthew D Wodrich; Markus Reiher; Clémence Corminboeuf
Journal:  Chem Sci       Date:  2022-05-18       Impact factor: 9.969

Review 2.  Ruthenium-Catalyzed Cycloadditions to Form Five-, Six-, and Seven-Membered Rings.

Authors:  Rosalie S Doerksen; Tomáš Hodík; Guanyu Hu; Nancy O Huynh; William G Shuler; Michael J Krische
Journal:  Chem Rev       Date:  2021-02-12       Impact factor: 60.622

3.  Catalytic Atroposelective C7 Functionalisation of Indolines and Indoles.

Authors:  Saad Shaaban; Christian Merten; Herbert Waldmann
Journal:  Chemistry       Date:  2021-11-05       Impact factor: 5.020

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.